Screener
Amphastar Pharmaceuticals AMPH EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Amphastar Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:50 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001297184-26-000047
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Income tax provision | 8,196 | 8,305 | 11,828 | 13,882 |
| Net income | $30,348 | $31,030 | $36,768 | $56,315 |
| Net income per share: | ||||
| Basic | $0.69 | $0.66 | $0.83 | $1.19 |
| Diluted | $0.67 | $0.64 | $0.81 | $1.15 |
| Weighted-average shares used to compute net income per share: | ||||
| Basic | 43,644 | 46,949 | 44,483 | 47,295 |
| Diluted | 44,225 | 48,128 | 45,341 | 49,009 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Amphastar Pharmaceuticals's EPS (diluted)?
- Amphastar Pharmaceuticals (AMPH) reported EPS (diluted) of $0.67 in Q2 2026.
- How has Amphastar Pharmaceuticals's EPS (diluted) changed year-over-year?
- Amphastar Pharmaceuticals's EPS (diluted) increased by 4.7% year-over-year, from $0.64 to $0.67.
- What is the long-term trend for Amphastar Pharmaceuticals's EPS (diluted)?
- Over 4 years (2021 to 2025), Amphastar Pharmaceuticals's EPS (diluted) has grown at a 12.9% compound annual growth rate (CAGR), from $1.25 to $2.03.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Amphastar Pharmaceuticals's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude